Molecular and cellular aspects of sepsis-induced immunosuppression

Journal of Molecular Medicine

Volumn 86, Issue 5, 2008, Pages 495-506

  Wang, Tisha S ^a   Deng, Jane C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokines; Immunosuppression; Sepsis

Indexed keywords

AFELIMOMAB; CASPASE 12; CD11B ANTIGEN; CD14 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CORTICOSTEROID; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR3 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ASPERGILLOSIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE EXACERBATION; ENDOTOXEMIA; HEMORRHAGIC SHOCK; HEREDITY; HOST SUSCEPTIBILITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION SENSITIVITY; INJURY; INNATE IMMUNITY; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PERITONEUM MACROPHAGE; PHENOTYPE; PLASMAPHERESIS; REVIEW; SECONDARY INFECTION; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION;

ANIMALS; HUMANS; IMMUNE TOLERANCE; SEPSIS;

EID: 43049087343     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-007-0300-4     Document Type: Review

References (121)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310
2. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554
3. Bone RC (1991) Gram-negative sepsis. Background, clinical features, and intervention. Chest 100:802-808
4. Thomas L (1972) Germs. N Engl J Med 287:553-555
5. Bone RC, Balk RA, Cerra FB et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655
6. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319:397-400
7. Cronin L, Cook DJ, Carlet J et al (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23:1430-1439
8. Fisher CJ Jr., Agosti JM, Opal SM et al (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697-1702
9. Remick DG (2003) Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des 9:75-82
10. Bone RC (1996) Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 125:680-687
11. Benjamim CF, Hogaboam CM, Lukacs NW, Kunkel SL (2003) Septic mice are susceptible to pulmonary aspergillosis. Am J Pathol 163:2605-2617
12. Fink MP, Heard SO (1990) Laboratory models of sepsis and septic shock. J Surg Res 49:186-196
13. Volk HD, Reinke P, Krausch D et al (1996) Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22(Suppl 4):S474-481
14. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150
15. Evans GF, Snyder YM, Butler LD, Zuckerman SH (1989) Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circ Shock 29:279-290
16. Villa P, Sartor G, Angelini M et al (1995) Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin Diagn Lab Immunol 2:549-553
17. Osuchowski MF, Welch K, Siddiqui J, Remick DG (2006) Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 177:1967-1974
18. Xiao H, Siddiqui J, Remick DG (2006) Mechanisms of mortality in early and late sepsis. Infect Immun 74:5227-5235
19. van der Poll T, van Deventer SJ (1999) Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 13:413-426 ix
20. Opal SM, DePalo VA (2000) Anti-inflammatory cytokines. Chest 117:1162-1172
21. Gogos CA, Drosou E, Bassaris HP, Skoutelis A (2000) Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181:176-180
22. Monneret G, Finck ME, Venet F et al (2004) The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 95:193-198
23. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M (1998) Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 351:950-953
24. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ (1999) IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 162:392-399
25. Saleh M, Vaillancourt JP, Graham RK et al (2004) Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 429:75-79
26. Saleh M, Mathison JC, Wolinski MK et al (2006) Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 440:1064-1068
27. Cavaillon JM, Adib-Conquy M (2005) Monocytes/macrophages and sepsis. Crit Care Med 33:S506-509
28. Astiz M, Saha D, Lustbader D, Lin R, Rackow E (1996) Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J Lab Clin Med 128:594-600
29. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747-1754
30. Ayala A, Kisala JM, Felt JA, Perrin MM, Chaudry IH (1992) Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin 1, interleukin 6, or tumor necrosis factor) during sepsis? Arch Surg 127:191-196 discussion 196-197
31. Fumeaux T, Pugin J (2002) Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 166:1475-1482
32. Lin RY, Astiz ME, Saxon JC, Rackow EC (1993) Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression. Chest 104:847-853
33. Fumeaux T, Pugin J (2006) Is the measurement of monocytes HLA-DR expression useful in patients with sepsis? Intensive Care Med 32:1106-1108
34. Monneret G, Lepape A, Voirin N et al (2006) Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 32:1175-1183
35. Venet F, Tissot S, Debard AL et al (2007) Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: correlation with severity and secondary septic shock. Crit Care Med 35:1910-1917
36. Chen GH, Reddy RC, Newstead MW, Tateda K, Kyasapura BL, Standiford TJ (2000) Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense. J Immunol 165:6496-6503
37. Docke WD, Randow F, Syrbe U et al (1997) Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678-681
38. Kox WJ, Bone RC, Krausch D et al (1997) Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 157:389-393
39. Hornell TM, Beresford GW, Bushey A, Boss JM, Mellins ED (2003) Regulation of the class II MHC pathway in primary human monocytes by granulocyte- macrophage colony-stimulating factor. J Immunol 171:2374-2383
40. Pangault C, Le Tulzo Y, Tattevin P, Guilloux V, Bescher N, Drenou B (2006) Down-modulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock. Crit Care Med 34:1193-1201
41. Nierhaus A, Montag B, Timmler N et al (2003) Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 29:646-651
42. Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW (2002) A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 166:138-143
43. Ding Y, Chung CS, Newton S et al (2004) Polymicrobial sepsis induces divergent effects on splenic and peritoneal dendritic cell function in mice. Shock 22:137-144
44. Hotchkiss RS, Tinsley KW, Swanson PE et al (2002) Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 168:2493-2500
45. Tinsley KW, Grayson MH, Swanson PE et al (2003) Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells. J Immunol 171:909-914
46. Efron PA, Martins A, Minnich D et al (2004) Characterization of the systemic loss of dendritic cells in murine lymph nodes during polymicrobial sepsis. J Immunol 173:3035-3043
47. Wen H, Hogaboam CM, Gauldie J, Kunkel SL (2006) Severe sepsis exacerbates cell-mediated immunity in the lung due to an altered dendritic cell cytokine profile. Am J Pathol 168:1940-1950
48. Benjamim CF, Lundy SK, Lukacs NW, Hogaboam CM, Kunkel SL (2005) Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood 105:3588-3595
49. Flohe SB, Agrawal H, Schmitz D, Gertz M, Flohe S, Schade FU (2006) Dendritic cells during polymicrobial sepsis rapidly mature but fail to initiate a protective Th1-type immune response. J Leukoc Biol 79:473-481
50. Kawasaki T, Hubbard WJ, Choudhry MA, Schwacha MG, Bland KI, Chaudry IH (2006) Trauma-hemorrhage induces depressed splenic dendritic cell functions in mice. J Immunol 177:4514-4520
51. Muller Kobold AC, Tulleken JE, Zijlstra JG et al (2000) Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med 26:883-892
52. Benjamim CF, Ferreira SH, Cunha FQ (2000) Role of nitric oxide in the failure of neutrophil migration in sepsis. J Infect Dis 182:214-223
53. Tavares-Murta BM, Zaparoli M, Ferreira RB et al (2002) Failure of neutrophil chemotactic function in septic patients. Crit Care Med 30:1056-1061
54. Terregino CA, Lubkin CL, Thom SR (1997) Impaired neutrophil adherence as an early marker of systemic inflammatory response syndrome and severe sepsis. Ann Emerg Med 29:400-403
55. Goodman R, Cummings C, Frevert C, Quan J, Martin T (1999) Functional significance of CXCR2 downregulation on neutrophils from patients with severe sepsis. Chest 116:111S-112S
56. Reddy RC, Chen GH, Tekchandani PK, Standiford TJ (2001) Sepsis-induced immunosuppression: from bad to worse. Immunol Res 24:273-287
57. Tsai WC, Strieter RM, Mehrad B, Newstead MW, Zeng X, Standiford TJ (2000) CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun 68:4289-4296
58. Hoesel LM, Neff TA, Neff SB et al (2005) Harmful and protective roles of neutrophils in sepsis. Shock 24:40-47
59. Root RK, Lodato RF, Patrick W et al (2003) Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 31:367-373
60. Hotchkiss RS, Swanson PE, Freeman BD et al (1999) Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27:1230-1251
61. Hotchkiss RS, Tinsley KW, Swanson PE et al (1999) Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A 96:14541-14546
62. Hotchkiss RS, Tinsley KW, Swanson PE et al (2001) Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166:6952-6963
63. Rajan G, Sleigh JW (1997) Lymphocyte counts and the development of nosocomial sepsis. Intensive Care Med 23:1187
64. Hotchkiss RS, Chang KC, Swanson PE et al (2000) Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 1:496-501
65. Pinsky MR (2004) Dysregulation of the immune response in severe sepsis. Am J Med Sci 328:220-229
66. Meakins JL, Pietsch JB, Bubenick O et al (1977) Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg 186:241-250
67. Barker RN, Erwig L, Pearce WP, Devine A, Rees AJ (1999) Differential effects of necrotic or apoptotic cell uptake on antigen presentation by macrophages. Pathobiology 67:302-305
68. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I (1997) Immunosuppressive effects of apoptotic cells. Nature 390:350-351
69. Hotchkiss RS, Chang KC, Grayson MH et al (2003) Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci U S A 100:6724-6729
70. Poltorak A, He X, Smirnova I et al (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088
71. Arbour NC, Lorenz E, Schutte BC et al (2000) TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25:187-191
72. Schroder NW, Schumann RR (2005) Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5:156-164
73. Agnese DM, Calvano JE, Hahm SJ et al (2002) Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 186:1522-1525
74. Lorenz E, Mira JP, Frees KL, Schwartz DA (2002) Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162:1028-1032
75. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA (2000) A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 68:6398-6401
76. Cavaillon JM, Adib-Conquy M (2006) Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 10:233
77. Lehner MD, Morath S, Michelsen KS, Schumann RR, Hartung T (2001) Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J Immunol 166:5161-5167
78. Mizel SB, Snipes JA (2002) Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from toll-like receptor 5. J Biol Chem 277:22414-22420
79. Sato S, Nomura F, Kawai T et al (2000) Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol 165:7096-7101
80. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr., Medzhitov R, Flavell RA (2002) IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110:191-202
81. Sato S, Takeuchi O, Fujita T, Tomizawa H, Takeda K, Akira S (2002) A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. Int Immunol 14:783-791
82. Nakayama K, Okugawa S, Yanagimoto S et al (2004) Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages. J Biol Chem 279:6629-6634
83. Wang JH, Doyle M, Manning BJ, Di Wu Q, Blankson S, Redmond HP (2002) Induction of bacterial lipoprotein tolerance is associated with suppression of toll-like receptor 2 expression. J Biol Chem 277:36068-36075
84. Li L, Cousart S, Hu J, McCall CE (2000) Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells. J Biol Chem 275:23340-23345
85. Medvedev AE, Lentschat A, Wahl LM, Golenbock DT, Vogel SN (2002) Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 169:5209-5216
86. Adib-Conquy M, Adrie C, Moine P et al (2000) NF-kappaB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med 162:1877-1883
87. Ziegler-Heitbrock HW, Wedel A, Schraut W et al (1994) Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. J Biol Chem 269:17001-17004
88. Deng JC, Cheng G, Newstead MW et al (2006) Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 116:2532-2542
89. Escoll P, del Fresno C, Garcia L et al (2003) Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun 311:465-472
90. Appoloni O, Vincent JL, Duchateau J (2002) Response of tumour necrosis factor-alpha to delayed in vitro monocyte stimulation in patients with septic shock is related to outcome. Clin Sci (Lond) 102:315-320
91. Heagy W, Nieman K, Hansen C, Cohen M, Danielson D, West MA (2003) Lower levels of whole blood LPS-stimulated cytokine release are associated with poorer clinical outcomes in surgical ICU patients. Surg Infect (Larchmt) 4:171-180
92. Broad A, Jones DE, Kirby JA (2006) Toll-like receptor (TLR) response tolerance: a key physiological "damage limitation" effect and an important potential opportunity for therapy. Curr Med Chem 13:2487-2502
93. Adib-Conquy M, Cavaillon JM (2002) Gamma interferon and granulocyte/monocyte colony-stimulating factor prevent endotoxin tolerance in human monocytes by promoting interleukin-1 receptor-associated kinase expression and its association to MyD88 and not by modulating TLR4 expression. J Biol Chem 277:27927-27934
94. Bosisio D, Polentarutti N, Sironi M et al (2002) Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood 99:3427-3431
95. Stuber F, Klaschik S, Lehmann LE, Schewe JC, Weber S, Book M (2005) Cytokine promoter polymorphisms in severe sepsis. Clin Infect Dis 41(Suppl 7):S416-420
96. Arcaroli J, Fessler MB, Abraham E (2005) Genetic polymorphisms and sepsis. Shock 24:300-312
97. Westendorp RG, Langermans JA, Huizinga TW et al (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170-173
98. Pinsky MR (2007) Genetics of individualizing patient care. Crit Care Med 35:287-280
99. Barber RC, Chang LY, Arnoldo BD et al (2006) Innate immunity SNPs are associated with risk for severe sepsis after burn injury. Clin Med Res 4:250-255
100. van Eijk LT, Dorresteijn MJ, Smits P, van der Hoeven JG, Netea MG, Pickkers P (2007) Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med 35:1464-1469
101. Lin J, Yao YM, Yu Y et al (2007) Effects of CD14-159 C/T polymorphism on CD14 expression and the balance between proinflammatory and anti-inflammatory cytokines in whole blood culture. Shock 28:148-153
102. Heesen M, Bloemeke B, Schade U, Obertacke U, Majetschak M (2002) The -260 C→T promoter polymorphism of the lipopolysaccharide receptor CD14 and severe sepsis in trauma patients. Intensive Care Med 28:1161-1163
103. Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L (2002) Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 30:969-973
104. Kumpf O, Hamann L, Schlag PM, Schumann RR (2006) Pre- and postoperative cytokine release after in vitro whole blood lipopolysaccharide stimulation and frequent toll-like receptor 4 polymorphisms. Shock 25:123-128
105. Papathanassoglou ED, Giannakopoulou MD, Bozas E (2006) Genomic variations and susceptibility to sepsis. AACN Adv Crit Care 17:394-422
106. Osuchowski MF, Welch K, Yang H, Siddiqui J, Remick DG (2007) Chronic sepsis mortality characterized by an individualized inflammatory response. J Immunol 179:623-630
107. Quartin AA, Schein RM, Kett DH, Peduzzi PN (1997) Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 277:1058-1063
108. Braun L, Riedel AA, Cooper LM (2004) Severe sepsis in managed care: analysis of incidence, one-year mortality, and associated costs of care. J Manag Care Pharm 10:521-530
109. Angele MK, Chaudry IH (2005) Surgical trauma and immunosuppression: pathophysiology and potential immunomodulatory approaches. Langenbecks Arch Surg 390:333-341
110. Angele MK, Faist E (2002) Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. Crit Care 6:298-305
111. Munford RS, Pugin J (2001) Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 163:316-321
112. Hinshaw LB, Solomon LA, Freeny PC, Reins DA (1967) Endotoxin shock. Hemodynamic and survival effects of methylprednisolone. Arch Surg 94:61-66
113. Bone RC, Fisher CJ Jr., Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653-658
114. Group TVASSCS (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 317:659-665
115. Annane D, Sebille V, Charpentier C et al (2002) Effect of treatment with low doses of hydrocortisone and fluorocortisone on mortality in patients with septic shock. JAMA 288:862-871
116. Panacek EA, Marshall JC, Albertson TE et al (2004) Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 32:2173-2182
117. Goebel A, Kavanagh E, Lyons A et al (2000) Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann Surg 231:253-261
118. O'Suilleabhain C, O'Sullivan ST, Kelly JL, Lederer J, Mannick JA, Rodrick ML (1996) Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury. Surgery 120:290-296
119. Hackam DG, Mamdani M, Li P, Redelmeier DA (2006) Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 367:413-418
120. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ (2006) Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. Br Med J 333:999
121. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG (2007) Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 7:358-368